In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates

키워드

참고문헌 (40)

1. Lister PD, "Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms", Clin Microbiol Rev, 22, pp.582~610 (2009)
2. Peleg AY, "Acinetobacter baumannii: emergence of a successful pathogen", Clin Microbiol Rev, 21, pp.538~582 (2008)
3. 이경원, "Further Increases in Carbapenem-, Amikacin-, and Fluoroquinolone-Resistant Isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009", Yonsei Medical Journal, 52(5), pp.793~802 (2011), 연세대학교의과대학
4. Huh K, "Continuous increase of the antimicrobial resistance among gram-negative pathogens causing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases (KONSID)", Diagn Microbiol Infect Dis, 76, pp.477~482 (2013)
5. Koch-Weser J, "Adverse effects of sodium colistimethate. Manifestations and specific rates during 317 courses of therapy", Ann Intern Med, 72, pp.857~868 (1970)
6. Li J, "Old polymyxins are back: is resistance close?", Clin Infect Dis, 43, pp.663~664 (2006)
7. Bergen PJ, "Dosing of colistin-back to basic PK", PD, 2011, pp.11, 464~469
8. Taccone FS, "Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline", Eur J Clin Microbiol Infect Dis, 25, pp.257~260 (2006)
9. Dean CR, "Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1", Antimicrob Agents Chemother, 47, pp.972~978 (2003)
10. Navon-Venezia S, "High tigecycline resistance in multidrug-resistant Acinetobacter baumannii", J Antimicrob Chemother, 59, pp.772~774 (2007)
11. Peleg AY, "Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii", Antimicrob Agents Chemother, 51, pp.2065~2069 (2007)
12. Petrosillo N, "Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies", Clin Microbiol Infect, 14, pp.816~827 (2008)
13. Tamma PD, "Combination therapy for treatment of infections with gram-negative bacteria", Clin Microbiol Rev, 25, pp.450~470 (2012)
14. Zavascki AP, "Combination therapy for carbapenem-resistant Gram-negative bacteria", Expert Rev Anti Infect Ther, 11, pp.1333~1353 (2013)
15. Zusman O, "Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems", Antimicrob Agents Chemother, 57, pp.5104~5111 (2013)
16. Clinical and Laboratory Standards Institute, "Performance standard for antimicrobial susceptibility testing", Clinical and Laboratory Standards Institute, ~ (2013)
17. Lee K, "Improved performance of the modified Hodge test with MacConkey agar for screening carbapenemase-producing Gram-negative bacilli", J Microbiol Methods, 83, pp.149~152 (2010)
18. Lee K, "Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp", J Clin Microbiol, 41, pp.4623~4629 (2003)
19. Lee K, "Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea", Int J Antimicrob Agents, 33, pp.520~524 (2009)
20. Hindler JF, "Clinical microbiology procedures handbook", pp.5.0.1~5.18.2.1 (2010), ASM Press
21. Biswas S, "Colistin: an update on the antibiotic of the 21st century", Expert Rev Anti Infect Ther, 10, pp.917~934 (2012)
22. Dhariwal AK, "Colistin: re-emergence of the ‘forgotten’ antimicrobial agent", J Postgrad Med, 59, pp.208~215 (2013)
23. García-Quintanilla M, "Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide", Antimicrob Agents Chemother, 58, pp.2972~2975 (2014)
24. Lee JY, "Genomic variations between colistin-susceptible and -resistant Pseudomonas aeruginosa clinical isolates and their effects on colistin resistance", J Antimicrob Chemother, 69, pp.1248~1256 (2014)
25. Matthaiou DK, "Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study", Crit Care Med, 36, pp.807~811 (2008)
26. Kim Y, "In vivo emergence of colistin resistance in Acinetobacter baumannii clinical isolates of sequence type 357 during colistin treatment", Diagn Microbiol Infect Dis, 79, pp.362~366 (2014)
27. Galani I, "Colistin susceptibility testing by Etest and disk diffusion methods", Int J Antimicrob Agents, 31, pp.434~439 (2008)
28. Hindler JA, "Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli", J Clin Microbiol, 51, pp.1678~1684 (2013)
29. Landman D, "Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B", J Antimicrob Chemother, 55, pp.954~957 (2005)
30. Gunderson BW, "Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model", Antimicrob Agents Chemother, 47, pp.905~909 (2003)
31. Timurkaynak F, "In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units", Int J Antimicrob Agents, 27, pp.224~228 (2006)
32. Cirioni O, "Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain", Antimicrob Agents Chemother, 51, pp.2005~2010 (2007)
33. Tascini C, "Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections", J Chemother, 16, pp.282~287 (2004)
34. Choi JY, "Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii", Clin Microbiol Infect, 10, pp.1098~1101 (2004)
35. Song JY, "Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model", Int J Antimicrob Agents, 33, pp.33~39 (2009)
36. Pachón-Ibáñez ME, "Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains", Eur J Clin Microbiol Infect Dis, 30, pp.895~901 (2011)
37. Liang W, "Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients", BMC Infect Dis, 11, pp.109~ (2011)
38. Lee HJ, "Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic", pharmacodynamic model, 2013, pp.57, 3738~3745
39. Wareham DW, "In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases", Ann Clin Microbiol Antimicrob, 5, pp.10~ (2006)
40. Khawcharoenporn T, "Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia", Int J Antimicrob Agents, 43, pp.378~382 (2014)

관련 논문AI추천